Africa Cancer Therapeutics Market Report (2021–2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The Cancer Therapeutics Market size is expected to reach US$ 4,977.42 million by 2031 from US$ 2,498.44 million in 2024. The market is estimated to record a CAGR of 10.4% from 2025 to 2031.

Executive Summary and Africa Cancer Therapeutics Market Analysis:

The cancer therapeutics market in Africa is experiencing notable progress, driven by an increasing burden of cancer cases, an expanding healthcare infrastructure, and growing access to advanced medical treatments. Africa is home to diverse countries with varying healthcare systems and economic statuses, adding to the complexity of the region’s cancer therapeutics landscape complex. Cancer is becoming one of the leading causes of morbidity and mortality across the continent, with countries such as South Africa, Egypt, and Nigeria witnessing significant rises in cancer cases. However, challenges such as limited access to healthcare, insufficiency of early detection programs, and a lack of cancer awareness remain key barriers to cancer care.

Africa Cancer Therapeutics Market Segmentation Analysis:

Key segments that contributed to the derivation of the cancer therapeutics market analysis are therapy type, indication, and distribution channel.

By therapy type, the cancer therapeutics market is segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. The chemotherapy segment dominated the market in 2024. In terms of indications, the market is segmented into blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. The lung cancer segment held the largest share of the market in 2024. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospital pharmacies segment held the largest share of the market in 2024.

Africa Cancer Therapeutics Market Outlook

A significant rise in cancer cases in the region drives the need for cancer therapeutics. According to the government of UAE, ~4,500 new cases of cancer are reported every year in the country. The International Agency for Research on Cancer stated that the UAE recorded 4,807 new cancer cases in 2020. As per GLOBOCAN 2020 data, the country recorded ~1,030 new breast cancer cases, representing 21.4% of all new cases. The demand for cancer treatments, both conventional and innovative, is surging due to increasing cancer cases, coupled with an aging population and lifestyle factors that contribute to cancer risks, such as smoking and poor dietary habits.

Governments of various countries of the Africa are investing heavily in healthcare infrastructure and cancer control programs. For instance, the government of Kuwait has been actively investing in efforts to enhance the cancer treatment infrastructure. The Ministry of Health (MOH) has prioritized cancer care by establishing specialized treatment centers such as the Kuwait Cancer Control Center, which provides a wide range of services, including chemotherapy and immunotherapy. In October 2021, the National Bank of Kuwait (NBK) launched an annual campaign during breast cancer awareness month to promote women's health. The campaign is part of the Bank's ongoing campaign to raise social awareness regarding breast cancer and promote its ways of prevention.

Africa Cancer Therapeutics Market Country Insights

Based on region, the Africa cancer therapeutics market is further segmented into South Africa, Egypt, Algeria, and Nigeria. South Africa held the largest share in 2024.

South Africa is one of the major economies in the Middle East & Africa; the country had a GDP of US$ 377.78 billion in 2024. Healthcare accounts for ~8.5% of the national GDP, holding the second-largest share of the overall GDP of the country. As the government and private sectors increase funding to improve healthcare infrastructure, there is greater demand for therapeutics.

Cancer remains one of the leading causes of death in South Africa, with common types including breast, prostate, cervical, and lung cancer. According to the GLOBOCAN 2020 data, ~108,168 new cancer cases were diagnosed, and 56,802 cancer-related mortality occurred in the country in 2020. The South African government, through its public health system, has been working to tackle the rising burden of cancer by implementing a range of initiatives aimed at improving access to cancer care and encouraging innovations in cancer therapies.

Africa Cancer Therapeutics Market Company Profiles

Astellas Pharma Inc; Eli Lilly and Co; Novartis AG; Merck KGaA.; Johnson & Johnson; AstraZeneca; Pfizer Inc; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd; and AbbVie are among the key players operating in the market. These companies are engaged in collaborative drug development to bring novel therapeutics for cancer in the market, aiming to stay ahead on competitive edge.

Africa Cancer Therapeutics Market Research Methodology:

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

Company websites, annual reports, financial statements, broker analyses, and investor presentations Industry trade journals and other relevant publications Government documents, statistical databases, and market reports News articles, press releases, and webcasts specific to companies operating in the marketNote:All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

Business Market Insights conducts a significant number of primary interviews each year with industry stakeholders and experts to validate and analyze the data and gain valuable insights. These research interviews are designed to:

Refine findings from secondary research Enhance the expertise and market understanding of the analysis team Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects Primary research is conducted via email interactions and telephone interviews with industry experts across various markets, categories, segments, and sub-segments in different regions. Participants typically include:

Industry stakeholders:

Vice Presidents, business development managers, market intelligence managers, and national sales managers External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise Key Sources Referred:

The World Bank World Development Indicators World Health Organization Global Cancer Observatory The Cancer Atlas